Goldman Sachs analysts added Argenx (ARGX) to the firm’s European Conviction List as part of its monthly update. Goldman views current share levels as a “compelling entry point into a differentiated growth story.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires
- Argenx Files 2025 Annual Report and Links Dutch Filing to U.S. Registrations
- Argenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact
- Argenx Ends Phase 3 Thyroid Eye Disease Trial, Resetting Expectations for Efgartigimod
- Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod